Experiment 1034270
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | COONLEY,CJ: BAINS,M: HEELAN,R: DUKEMAN,M: KELSEN,DP:. (1983). PHASE 2 STUDY OF ETOPOSIDE IN THE TREATMENT OF ESOPHAGEAL CARINOMA.. 67(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE II STUDY OF THE TITLE COMPOUND IN 23 PATIENTS WITH HISTOLOGICALLY PROVED ECE WERE ENTERED IN THIS STUDY. ADMINISTRATION WAS BY SLOW IV INFUSION(45 MINUTES) ON DAYS 1,3 AND 5 OF EACH 21 DAY CYCLE. OF 23 PATIENTS ENTERED, THREE WERE CONSIDERED INEVALUABLE FOR RESPONSE BECAUSE OF EARLY(2 WEEKS) DISEASE RELATED DEATHS. FOURTEEN PATIENTS HAD RECEIVED PRIOR CHEMOTHERAPY,MOST WITH A COMBINATION OF VINDESINE, CISPLATIN AND BLEOMYCIN. 6 EVALUABLE PATIENTS HAD RECEIVED NO PRIOR CHEMOTHERAPY. TOXICITY WAS PRIMARILY HEMATOLOGIC AND OCCURRED USUALLY WITHIN 10-21 DAYS OF THE FIRST DOSE. 2 PATIENTS DIED OF PNEUMONIA DURING THE WBC COUNT NADIR. ALOPECIA WAS FREQUENTLY OBSERVED. NAUSEA AND VOMITING WERE UNCOMMON. NO COMPLETE OR PARTIAL ANTITUMOR RESPONSES WERE SEEN IN THIS TRAIL. TWO OF SIX PATIENTS WHO HAD NOT RECEIVED PRIOR CHEMOTHERAPY EXPERIENCED BRIEF MINOR RESPONSES. AMONG 14 PREVIOUSLY TREATED PATIENTS THERE WAS ONE WITH A MINOR BRIEF RESPONSE AND ONE WITH STABLE DISEASE FOR 2 MONTHS. THESE FINDINGS PRECLUDE A 15% RESPONSE FREQUENCY IN THIS POPULATION WITH EPIDERMOID CARCINOMA OF THE ESOPHAGUS. |
| Dose amount | 100.0 MG |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |